Eguchi Yuichiro, Wong Gabriel, Lee I-Heng, Akhtar Omar, Lopes Ricardo, Sumida Yoshio
Liver Center, Saga University Hospital, Saga, Japan.
Department of Internal Medicine, Saga University, Japan.
Hepatol Res. 2021 Jan;51(1):19-30. doi: 10.1111/hepr.13583. Epub 2020 Dec 9.
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality in Japan. As the treatment of viral hepatitis improves, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are rapidly becoming leading causes of HCC in Japan. This structured review aims to characterize the morbidity and mortality of HCC and other malignant and non-malignant complications among Japanese NAFLD and NASH patients.
An English and Japanese structured search of published works was undertaken in PubMed, Embase, and Ichushi Web databases, identifying 6553 studies, 34 of which met predefined inclusion criteria.
Hepatocellular carcinoma was the most common incident malignancy among NAFLD/NASH patients, with higher incidence in patients with advanced/severe fibrosis (F3/F4) of 10.5%-20.0%. Although NASH results in a lower HCC cumulative incidence than hepatitis C virus (HCV) (11.3% vs. 30.5%), they have similar impacts on health outcomes, including overall mortality. Among Japanese NASH patients, HCC was found to be the main driver of mortality (40.0% in 2.7 years in NASH-HCC). With longer follow-up, higher mortality rates are observed in F3/4 patients: 25.0% in NASH F3/F4 versus 0.0% in NASH F0/2 over 7.7 years. The NASH-HCC patients also have a higher post-operative mortality than HCV-HCC patients. Additionally, NAFLD/NASH patients had higher rates of cardiovascular disease than non-NAFLD/NASH controls, and slightly higher rates of gastric cancer than HCV patients.
Hepatocellular carcinoma is the most common malignancy and cause of death among NAFLD/NASH patients in Japan, with higher mortality observed among those with advanced disease and complications. Early identification and effective treatments are needed.
肝细胞癌(HCC)是日本发病和死亡的重要原因。随着病毒性肝炎治疗方法的改进,非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)正迅速成为日本HCC的主要病因。本系统评价旨在描述日本NAFLD和NASH患者中HCC以及其他恶性和非恶性并发症的发病情况和死亡率。
在PubMed、Embase和Ichushi Web数据库中对已发表的文献进行英文和日文的系统检索,共识别出6553项研究,其中34项符合预先设定的纳入标准。
肝细胞癌是NAFLD/NASH患者中最常见的新发恶性肿瘤,在晚期/重度纤维化(F3/F4)患者中的发病率较高,为10.5%-20.0%。虽然NASH导致的HCC累积发病率低于丙型肝炎病毒(HCV)(11.3%对30.5%),但它们对健康结局的影响相似,包括总体死亡率。在日本NASH患者中,HCC被发现是死亡的主要驱动因素(NASH-HCC患者在2.7年内死亡率为40.0%)。随着随访时间延长,F3/4患者的死亡率更高:在7.7年的时间里,NASH F3/F4患者的死亡率为25.0%,而NASH F0/2患者为0.0%。NASH-HCC患者术后死亡率也高于HCV-HCC患者。此外,NAFLD/NASH患者的心血管疾病发生率高于非NAFLD/NASH对照组,胃癌发生率略高于HCV患者。
肝细胞癌是日本NAFLD/NASH患者中最常见的恶性肿瘤和死亡原因,晚期疾病和并发症患者的死亡率更高。需要早期识别和有效治疗。